Lecanemab Extension Study for AD Offers Mixed Results
The lecanemab open-label extension trial for AD showed no new safety signals, but the placebo roll-over group failed to show the gains seen in the experimental arm.
Source: medscape.com
Page 15 - Double Blind Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Double Blind Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Double Blind Study Today - Breaking & Trending Today
FDA Approves New Antibiotic for Uncomplicated UTIs
The US Food and Drug Administration has approved pivmecillinam (Pivya) tablets to treat uncomplicated urinary tract infections in women.
Source: medscape.com
Drug for Overactive Bladder Recommended in Europe
Obgemsa is suitable for treating symptoms of an overactive bladder in adults, the European Medicines Agency has determined.
Source: medscape.com
Acurx Pharmaceuticals Announces Presentation of Ibezapolostat Phase 2 Clinical Trial Results at upcoming ESCMID 2024 Scientific Conference
/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...
Source: prnewswire.com
FDA Seeks More Information About RDEB Rx Under Review
Pz-cel, which comprises autologous, COL7A1 gene–corrected epidermal sheets, was designed to enable normal type VII collagen expression and facilitate wound healing and pain reduction in RDEB wounds.
Source: medscape.com